Systemic scleroderma: Review and updated approach and case description to addressing pulmonary arterial hypertension and idiopathic pulmonary fibrosis: A dual challenge in treatment.
Curr Probl Cardiol
; 49(4): 102404, 2024 Apr.
Article
en En
| MEDLINE
| ID: mdl-38232920
ABSTRACT
Pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), and scleroderma (SSc) are three interrelated medical conditions that can result in significant morbidity and mortality. Pulmonary hypertension, a condition marked by high blood pressure in the lungs, can lead to heart failure and other complications. Idiopathic pulmonary fibrosis, a progressive lung disease characterised by scarring of lung tissue, can cause breathing difficulties and impaired oxygenation. Scleroderma, an autoimmune disease, can induce thickening and hardening of the skin and internal organs, including the lungs, leading to pulmonary fibrosis and hypertension. Currently, there is no cure for any of these conditions. However, early detection and proper management can improve the quality of life and prognosis of a patient. This review focusses on PH and IPF in patients with SSc, providing information on the causes, symptoms, and treatment of these conditions, together with illustrative images. It also provides an overview of interrelated medical conditions PH, IPF, and SSc. It emphasises the importance of early detection and proper management to improve patient quality of life and prognosis.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Esclerodermia Sistémica
/
Fibrosis Pulmonar Idiopática
/
Hipertensión Arterial Pulmonar
/
Hipertensión
/
Hipertensión Pulmonar
Tipo de estudio:
Screening_studies
Aspecto:
Patient_preference
Límite:
Humans
Idioma:
En
Revista:
Curr Probl Cardiol
Año:
2024
Tipo del documento:
Article